Article Details
Retrieved on: 2021-03-30 12:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
A few weeks back, Pfizer out-licensed two of its antibody-drug conjugate (ADC) candidates, to be known as PYX-201 and PYX-203, to the biotech, while ...
Article found on: www.fiercebiotech.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here